JJC8-089

JJC8-089
Clinical data
Drug class	Dopamine reuptake inhibitor
Identifiers
	IUPAC name 1-[4-[2-[bis(4-fluorophenyl)methylsulfanyl]ethyl]piperazin-1-yl]propan-2-ol;
CAS Number	1627576-64-0 ;
PubChem CID	90389439;
ChemSpider	76721417;
ChEMBL	ChEMBL3916231;
Chemical and physical data
Formula	C22H28F2N2OS
Molar mass	406.54 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(CN1CCN(CC1)CCSC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)O;
	InChI InChI=1S/C22H28F2N2OS/c1-17(27)16-26-12-10-25(11-13-26)14-15-28-22(18-2-6-20(23)7-3-18)19-4-8-21(24)9-5-19/h2-9,17,22,27H,10-16H2,1H3; Key:MQDDJWTVOBHYHX-UHFFFAOYSA-N;

JJC8-089 is a dopamine reuptake inhibitor (DRI) that was derived from modafinil and is related to JJC8-016, JJC8-088, and JJC8-091.^[1]^[2] Its affinity (K_i) for the dopamine transporter (DAT) is 37.8 nM, for the norepinephrine transporter (NET) is 11,820 nM (313-fold lower than for the DAT), for the serotonin transporter (SERT) is 6,800 nM (180-fold lower than for the DAT), and for the sigma σ₁ receptor is 2.24 nM (17-fold higher than for the DAT).^[2]^[3] It also has significant affinity for several dopamine receptors.^[3] JJC8-089 has substantially higher affinity for the DAT than modafinil.^[1]^[2]^[3] The drug shows pro-motivational effects in animals.^[4]^[5] It was first described in the scientific literature by 2016.^[6]^[7]